Many drug development sponsors are interested in understanding how a digital biomarker strategy can improve patient-centricity their trial. However, may feel uncertain about where - and sometimes even why - to start. From concerns surrounding regulatory acceptance to defining digital endpoints and deployment plans and digital data collection, there are many factors to consider before incorporating new tools and processes into a clinical trial.This educational webinar is ideal for drug development sponsors that want to learn about the role of digital biomarkers in clinical trials and hear from several thought leaders as they discuss the key concerns with digital biomarker technologies, their implementation and regulatory acceptance. With a focus on strategic design and considerations for creating digital endpoints as part of an overarching deployment plan, the presenters will also cover many of the key pillars in the adoption and implementation of digital devices in a today's "new normal" with decentralized or hybrid clinical trial elements.